Local and systemic erythropoietin levels in complicated proliferative diabetic retinopathy
https://doi.org/10.21516/2072-0076-2016-9-2-55-60
Abstract
The levels of erythropoietin (EPO) in biological fluids were studied on 43 patients with diabetes mellitus type I and II who suffered from a variety of clinical manifestations of heavy proliferative diabetic retinopathy (PDR) which incuded stable PDR, 12 patients with rhegmatogenous retinal detachment and 15 healthy individuals The correlation of EPO levels with the clinical features of heavy PDR was noted only at the local level (intravitreally). The highest intraocular levels of EPO were associated with severe features of the disease, abundant vascularizarion of fibroglial tissue, and intraoperative hemorrhagic complications, which corroborates the theory of active participation of locally secreted EPO in ocular neoangiogenesis, including the progression of PDR // Russian Ophthalmological Journal, 2016; 2: 55-60. doi: 10.21516/2072-0076-2016-9-2-55-60 .
About the Authors
V. V. Neroev
Helmholtz Research Institute of Eye Diseases, Moscow, Russia
Russian Federation
Russian Federation
O. V. Zaitseva
Helmholtz Research Institute of Eye Diseases, Moscow, Russia
Russian Federation
Russian Federation
Z. V. Kurchaeva
Helmholtz Research Institute of Eye Diseases, Moscow, Russia
Russian Federation
Russian Federation
O. S. Slepova
Helmholtz Research Institute of Eye Diseases, Moscow, Russia
Russian Federation
Russian Federation
References
1. Garcia-Ramírez M., Hernández C., Ruiz-Meana M., et al. Erythropoietin protects retinal pigment epithelial cells against the increase of permeability induced by diabetic conditions: essential role of JAK2/ PI3K signaling. Cell Signal. 2011; 23: 1596-602.
2. Осиков М.В., Ахматов Л.В., Кривохижина В.Ю. Анализ гематологических эффектов эритропоэтина у больных хронической почечной недостаточностью, находящихся на диализе. Вестник Южно-Уральского государственного университета. Серия: Образование, здравоохранение, физическая культура. 2009; 20 (153): 79-82.
3. Fantacci M., Bianciardi P., Caretti A. Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. Proc Natl Acad Sci USA. 2006; 103(46): 17531-6.
4. Phillips J.K., Boyd R., Krockenberger M.B., et al. Progression of anemia and its relationship with renal function, blood pressure, and erythropoietin in rats with chronic kidney disease. Vet. Clin. Pathol. 2015; 44(3): 342-54.
5. Chiou T.T., Lee J.J., Wang M.C., et al. Genetic disposition and modifiable factors independently associated with anemia in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2015; 108(1): 164-9.
6. Donnelly S. Why is erythropoietin made in the kidney? The kidney functions as a critmeter. Am. J. Kidney Dis. 2001; 38: 415-25.
7. Asensio-Sánchez V.M., Gómez-Ramírez V., Morales-Gómez I. Erythropoietin concentrations in the vitreous body from patients with proliferative diabetic retinopathy. Arch Soc Esp Oftalmol. 2008; 83(3): 169-72.
8. Spivak J.L. Serum immunoreactive erythropoietin in heals and disease. J. Perinat. Med. 1995; 23(1-2): 13-7.
9. Maxwell P.H., Osmond M.K., Ptigh СW., et al. Identification of the renal erythropoietin producing cells using transgenic mice. Kidney Int. 1993; 44: 1149-62.
10. Brito P.L., Fioretto P., Drummond K., et al. Proximal tubular basement membrane with in insulin-dependent diabetes mellitus. Kidney Int. 1998; 53: 754-61.
11. Inomata S., Itoh M., Imai H., et al. Serum levels of erythropoietin as a novel marker reflecting the severity of diabetic nephropathy. Nephron. 1997; 75(4): 426-30.
12. Hernández C., Simó R. Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy. Endocrine. 2012 ; 41(2): 220-6.
13. Friedman E.A., L’Esperance F.A., Brown CD., Berman DH. Treating azotemia-induced anemia with erythropoietin improves diabetic eye disease. Kidney Int Suppl. 2003; 87: 57-63.
14. Massimetti C., Pontillo D., Feriozzi S., et al. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients. Blood Purif. 1998; 16(6): 317-24.
15. García-Ramírez M., Hernández C., Simó R. Expression of erythropoietin and its receptor in the human retina: a comparative study of diabetic and nondiabetic subjects. Diabetes Care. 2008; 31: 1189-94.
16. Chen J., Connor KM., Aderman CM., et al. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci. 2009; 50(3): 1329-35.
17. Kilic U., Kilic E., Soliz J., et al. Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/-2. FASEB J. 2005; 19(2): 249-51.
18. Chen J., Connor KM., Aderman CM., et al. Erythropoietin deficiency decreases vascular stability in mice. J. Clin Invest. 2008; 118(2): 526-33.
19. Taoufik E., Petit E., Divoux D. TNF receptor I sensitizes neurons to erythropoietin - and VEGF-mediated europrotection after ischemic and excitotoxic injury. Proc. Natl. Acad. Sci. USA. 2008; 22(105): 6185-90.
20. Shein N.A., Grigoriadis N., Alexandrovich AG., et al. Differential neuroprotective properties of endogenous and exogenous erythropoietin in a mouse model of traumatic brain injury. J Neurotrauma. 2008; 25(2): 112-23.
21. García-Ramírez M., Hernández C., Simó R. Expression of erythropoietin and its receptor in the human retina: a comparative study of diabetic and nondiabetic subjects. Diabetes Care. 2008; 31: 1189-94.
22. Kase S., Saito W., Ohgami K., et al. Expression of erythropoietin receptor in human epiretinal membrane of proliferative diabetic retinopathy. Br. J. Ophthalmol. 2007; 91: 1376-8.
23. Mohan N., Monickaraj F., Balasubramanyam M., et al. Imbalanced levels of angiogenic and angiostatic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy. J. Diabetes Complications. 2012; 26(5): 435-41.
24. Gholamhossein Y., Behrouz H., Asghar Z. Diabetic retinopathy risk factors: plasma erythropoietin as a risk factor for proliferative diabetic retinopathy. Korean J. Ophthalmol. 20 14; 28(5): 373-8.
25. Asensio-Sánchez V.M., Gómez-Ramírez V., Morales-Gómez I. Erythropoietin concentrations in the vitreous body from patients with proliferative diabetic retinopathy. Arch. Soc Esp Oftalmol. 2008; 83(3): 169-72.
26. Захаров Ю.М. Цитопротекторные функции эритропоэтина. Клиническая нефрология. 2009; 1: 16-21.
27. Watanabe D., Suzuma K., Matsui S., et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N. Engl. J. Med. 2005; 353(8): 782-92.
28. Semeraro F., Cancarini A., Morescalchi F., et al. Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy. Diabetes Metab. 2014; 40(6): 445-51.
29. Inomata Y., Hirata A., Takahashi E., et al. Elevated erythropoietin in vitreous with ischemic retinal diseases. Neuroreport. 2004; 15(5): 877-9.
30. Федеральные клинические рекомендации «Алгоритмы специализированной медицинской помощи больным сахарным диабетом». И.И. Дедов, М.В. Шестакова, ред. Российская ассоциация эндокринологов. Сахарный диабет. Москва; 2015: 1.
Review
For citations:
Neroev V.V., Zaitseva O.V., Kurchaeva Z.V., Slepova O.S. Local and systemic erythropoietin levels in complicated proliferative diabetic retinopathy. Russian Ophthalmological Journal. 2016;9(2):55-60. (In Russ.) https://doi.org/10.21516/2072-0076-2016-9-2-55-60
Views:
682
Email this article 